Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy as perioperative treatment for resectable locally advanced head and neck squamous cell carcinoma
ChiCTR2500108966Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 1-year Disease-Free Survival rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500108966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108966.